Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Active, not recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 12, 2021

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Dec 28, 2020

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Dec 23, 2020

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

Dec 22, 2020

Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Nov 9, 2020

Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors

Nov 5, 2020

Cellectar Biosciences to Present at Two Upcoming Investor Conferences

Sep 10, 2020

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

Sep 9, 2020

Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMA

Aug 17, 2020

Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

Aug 10, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...26
© 2021 Cellectar Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Q&A